LAVAL, QC, Sept. 21 /CNW Telbec/ - LAB Research Inc. ("LAB", "LAB Research" or the "Company"), (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced the nomination of Dr. Daniel P. Ménard as the new President for LAB Research Canada. Dr. Ménard will assume full responsibility of LAB Research Canada overall performance.
"We are thrilled to welcome Dr. Ménard to LAB Research Canada. Daniel is the perfect candidate to take over all operational and performance aspects of LAB Research Canada. His extensive scientific and operational experience will greatly complement and strengthen both the management and scientific team at our Canadian facility. " mentioned Mr. Luc Mainville, President and CEO of LAB Research Inc. "With activity levels at both our Canadian and Hungarian sites climbing to new historical levels following our successful expansions, the addition of Dr. Ménard will provide the Canadian site the necessary leadership to accelerate its growth. Daniel's prior experience as head of Algos and previously as head of MDS Pharma`s Pharmacology operations will help LAB Research maintain its strong commitment of making its brand a recognized symbol of excellence in research throughout the world. I look forward to welcoming him to the LAB Research family as we embark on our next phase of global development." added Mr. Mainville.
Dr. Ménard was until recently President and CEO of Algos Therapeutics Inc. where he spearheaded the transition of Algos' business model of proprietary drug development to a mature CRO; Algos Preclinical Services. Previously to Algos, Dr. Ménard was Vice-President, General Manager, Pharmacology & Metabolism resources at MDS Pharma Services where he managed a global organization of more than 250 people based in Canada, US and Taiwan, offering services to global drug discovery organizations. Earlier in his career, Dr. Ménard held senior scientific responsibilities at Astra Zeneca. Dr. Ménard has more than 18 years experience in science including 14 in the pharmaceutical industry at management level and has a background in lean and six sigma. Dr Ménard received his Ph.D. in pharmacology from the University of Sherbrooke, Quebec, Canada.
About LAB Research Inc.:
LAB Research is a Canadian global non-clinical contract research organization that provides contract research services to the pharmaceutical, biotechnology, agro-chemical, petro-chemical and industrial markets. LAB Research supports the development of its customers' products from three state-of-the-art facilities located in Canada, Denmark and Hungary.
LAB Research's shares trade on the TSX under the symbol "LRI", with 18.1 million shares outstanding.
This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB Research Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
SOURCE LAB RESEARCH INC.
For further information: For further information: visit LAB Research's website at www.labresearch.com, or contact: Luc Mainville, Chief Executive Officer,: (450) 973-2240 (ext. 1206), firstname.lastname@example.org; Frédéric Dumais, Partner, Jasmin-Dumais Financial Communications, (514) 862-1251, email@example.com